Medcura develops a platform of hemostatic products including surgical gels, foams, powders and textiles designed to quickly stop bleeding across surgical, trauma, battlefield and home use cases. Its lead product is LifeGel™ Absorbable Hemostatic Gel, intended for use in confined spaces such as spinal surgery because of its no-swell characteristic. The company has received FDA Breakthrough Device Designation for LifeGel and for its LifeFoam™ product. Medcura is a commercial-stage company led by CEO Jim Buck and Executive Chair Larry Tiffany and positions its platform to address a $2.8 billion worldwide biosurgery market for hemostatic agents. The company plans to use new funding to accelerate development of LifeGel, advance into a pivotal clinical trial, and pursue global commercialization. Medcura is based in Riverdale, MD. Medcura is a commercial-stage medical device company developing versatile hemostatic products for surgical, medical, and consumer applications. The company commercializes and develops a broad range of hemostatic and wound-treatment products, including Rapid-Seal, LifeFoam, and LifeGel. Rapid-Seal is becoming a market leader in high-performance, antibacterial first aid; LifeFoam is under development for internal traumatic and military injuries; LifeGel is under development for routine surgical use. Medcura is Riverdale, Md.-based and led by CEO Larry Tiffany. It raised $7.4M in financing that included the sale of Series A Preferred stock and common stock, with some investors participating via a Maryland Investment Incentive Program. The company intends to use the funds to expand its product line and develop its lead surgical candidate for clinical evaluation, leveraging its intellectual property estate, emergent FDA regulatory experience, and expanding manufacturing capabilities.

Total raised

$30M

Funding rounds

2

Latest round

Convertible Note

Latest activity

Apr 2024